Melanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity?

Medical Hypotheses

Volumn 81, Issue 5, 2013, Pages 846-850

  Bataille, Veronique ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Hemel Hempstead General Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERMEDIN;

ARTICLE; BODY WEIGHT; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; EMBRYO DEVELOPMENT; ENERGY EXPENDITURE; ENVIRONMENTAL FACTOR; GENDER; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INVOLUTION; LONGEVITY; MELANOCYTE; MELANOMA; NEVUS; PENETRANCE; PHENOTYPE; PHOTOAGING; RISK FACTOR; SENESCENCE; SKIN PIGMENTATION; SUN EXPOSURE;

HUMANS; INCIDENCE; MELANOMA; MORTALITY; NEVUS; RISK FACTORS; SKIN AGING; SUNLIGHT; VITAMIN D DEFICIENCY;

EID: 84886789957     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.05.031     Document Type: Article

References (53)

1. http://seer.cancer.gov/faststats/selections.php?run&output=2&data=1&statistic=2&year=200802&race=2&sex=1&age=1&series=cancer&cancer=53.
2. http://www.aihw.gov.au/cancer/#incidence.
3. Coory M., Baade P., Aitken J., et al. Trends in situ and invasive melanoma in Queensland, Australia 1982-2002. Cancer Causes Control 2006, 17:21-22.
4. Welch H.G., Black W.C. Overdiagnosis in cancer. J Natl Cancer Inst 2010, 102:605-613.
5. De Vries E., Boniol M., Dore J.F., et al. EUROCARE working group. Lower incidence but thicker melanomas in Eastern Europe before 1992: a comparison with Western Europe. Eur J Cancer 2004, 40:1045-1052.
6. Bataille V., Grulich A., Sasieni P., et al. The association between naevi and melanoma in populations with different sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998, 77:505-510.
7. Bulliard J.D., De Weck D., Fisch T., et al. Detailed distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series. Ann Oncol 2007, 18:789-794.
8. Gallagher R., McLean D.I., Yang C.P., et al. Anatomical distribution of acquired melanocytic naevi in white children. A comparison with melanoma. The vancouver mole study. Arch Dermatol 1990, 126:466-471.
9. Dodd A., Morelli J., Mokrohisky S.T., et al. Melanocytic nevi and sun exposure in a cohort of colarado children: anatomic distribution and site specific sunburn. Cancer Epidemiol Biomarkers Prev 2007, 16:2136-2143.
10. Larue L., de Vuyst F., Delmas V. Modeling melanoblast development. Cell Mol Life Sci 2013, 70:1067-1079.
11. O'Hara C, Birch J, McCabe M et al. Gender differences in survival among teenagers and young adults with CNS tumours. Cancer Outcomes Conference. Available from: 2012. http://www.ncin.org.uk/conference.
12. Gandini S., Sera F., Cattaruzza M.S., et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005, 41:45-60.
13. Gandini S., Sera F., Cattaruza P., et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005, 41:28-44.
14. Chang Y.M., Newton-Bishop J.A., Bishop D.T., et al. A pooled analysis of melanocytic naevus phenotype and the risk of cutaneous melanoma. Int J Cancer 2009, 124:420-428.
15. Cook A.L., Smith A.G., Smit D.J., et al. Co-expression of SOX9 and SOX 10 during melanocytic differentiation in vitro. Exp Cell Res 2005, 308:205-222.
16. Yokoyama S., Woods S.L., Boyle G.M., et al. A novel recurring mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480:99-103.
17. Bertolotto C., Lesueur F., Giuliano S., et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011, 480:94-98.
18. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2000, 27:949-954.
19. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
20. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
21. Blauer J., Buttner P., Murall R., et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumour and the degree of solar elastosis at the primary tumour site. Pigment Cell Melanoma Res 2011, 24:345-351.
22. Peeper D.S. Oncogene-induced senescence and melanoma. Where do we stand?. Pigment Cell Melanoma Res 2011, 24:1011-1107.
23. Tran S.L., Haferkamp S., Scurr L.L., et al. Absence of distinguishing senescence traits in human melanocytic nevi. J Invest Dermatol 2012, 132:2226-2234.
24. Goldstein A.M., Cahn M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma prone families from three continents. J Med Genet 2007, 44:99-106.
25. Harinck F., Kluijt I., van der Stoep N., et al. Indication for CDKN2A mutation analysis in familial pancreatic cancer families without melanomas. J Med Genet 2012, 49:362-365.
26. Goldstein A.M., Chan M., Harland M., et al. High risk melanoma susceptibility genes and pancreatic cancer, neural system tumors and uveal melanomas across GenoMEL. Cancer Res 2006, 15:9818-9828.
27. Falchi M., Bataille V., Hayward N., et al. Loci on chr 9p21 and 22q13 harbour alleles for the development of cutaneous nevi and melanoma. Nat Genet 2009, 41:915-919.
28. Bishop D.T., Demenais F., Iles M.M., et al. Genome wide association study identifies three loci associated with melanoma risk. Nat Genet 2009, 41:920-925.
29. Duffy D.L., Iles M.M., Glass D., et al. IRF4 variants have age specific effects on nevus count and predispose to melanoma. Am J Hum Genet 2010, 87:6-16.
30. Law M.H., MacGregor S., Hayward N.K. Melanoma genetics: Recent findings take us beyond well-traveled pathways. J Invest Dermatol 2012, 132:1763-1774.
31. Tomiyama H., Yoshino H., Ogaki K., et al. PLA2G6 variant in Parkinson disease. J Hum Genet 2011, 56:401-403.
32. Liu R., Gao X., Lu Y., Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011, 76:2002-2009.
33. Bataille V., Sasieni P., Grulich A., et al. Solar keratoses: a risk factor for melanoma but negative association with melanocytic naevi. Int J Cancer 1998, 78:8-12.
34. Whiteman D.C., Watt P., Purdie D.M., Hughes M.C., Hayward N.K., Green A.C. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003, 95:806-812.
35. Bataille V., Kato B.S., Falchi M., et al. Nevus size and number are associated with telomere length and represent potential markers of a reduced senescence in vivo. Cancer Epidemiol Biomarkers Prev 2007, 16:1499-1502.
36. Han J., Qureshi A.A., Prescott J., et al. A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 2009, 129:415-421.
37. Nan H., Du M., De Vivo I., et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res 2011, 71:6758-6763.
38. Law M.H., Montgomery G.W., Brown K.M., et al. Meta-analysis combining new and existing data sets confirms that TERT-CLPTM1L locus influences melanoma risk. J Invest Dermatol 2012, 132:485-487.
39. Horn S., Figl A., Rachakonda S., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
40. Huang F.W., Hodis E., Xu M.J., et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 6122:957-959.
41. Bohm M., Schiller M., Luger T.A. Non-pigmentary actions of alpha-melanocyte-stimulating hormone-lessons from the cutaneous melanocortin system. Cell Mol Biol 2006, 30:61-68.
42. Mountjoy K. Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. Biochem J 2010, 428:305-324.
43. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
44. Shors A.R., Solomon C., McTiernan A., White E. Melanoma risk in relation to height, weight and exercise (United States). Cancer Causes Controls 2001, 12:599-606.
45. Speliotes E., Willer C., Berndt S., et al. Association analyses of 249,796 individuals reveal eighteen new loci associated with body mass index. Nat Genet 2010, 42:937-948.
46. Iles M.M., Law M.H., Stacey S.N., et al. A variant in FTO shows an association with melanoma risk not due to BMI. Nat Genet 2013, 45:428-432.
47. Richards J.B., Valdes A.M., Gardner J.P., et al. Higher Vitamin D concentrations are associated with longer telomere length in women. Am J Clin Nutr 2007, 86:1420-1425.
48. Mai X.N., Cgen Y., Camargo C.A., Langhammer A. Cross-sectional and prospective cohort study of serum 25-hydroxyvitamin D level and obesity in adults: the HUNT study. Am J Epidemiol 2012, 175:1029-1036.
49. Glass D., Lens M., Swaminathan R., Spector T.D., Bataille V. Pigmentation and vitamin D metabolism in Caucasians: low vitamin D serum levels in fair skin types. PloS One 2009, 4:e6477.
50. Newton Bishop J.A., Beswick S., Randerson-Moor J., et al. Serum 25-hydroxyvitamin D3 levels are associated with brelsow thickness at presentation and survival from melanoma. J Clin Oncol 2009, 27:5439-5444.
51. Berger M.F., Hodis E., Heffernan T.P. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012, 485:502-506.
52. Jin P., Cai R., Zhou X., et al. Features of missense/nonsense mutations in exonic splicing enhancer sequences from cancer-related human genes. Mutat Res 2012, 740:6-12.
53. Gao L, Van den Oord JJ, Goeman JJ et al. Genome wide promoter methylation analyses identifies epignetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res 2013. http://dx.doi.org/10.1111/pcmr.12096. [Epub ahead of print].